トップページ > 産学連携推進部 > 研究実績 > 2023年 研究業績
2023年 研究業績
- S Nakagawa, T Katayama, L Jin, J Wu, K Kryukov, R Oyachi, J S Takeuchi, T Fujisawa, S Asano, M Komatsu, J I Onami, T Abe and M Arita.
SARS-CoV-2 HaploGraph: visualization of SARS-CoV-2 haplotype spread in Japan.
Genes Genet Syst.
https://doi.org/10.1266/ggs.23-00085 - S Yamamoto, K Matsuda, K Maeda, K Horii, K Okudera, Y Oshiro, N Inamura, T Nemoto, J S Takeuchi, Y Li, M Konishi, K Tsuchiya, H Gatanaga, S Oka, T Mizoue, H Sugiyama, N Aoyanagi, H Mitsuya, W Sugiura and N Ohmagari.
Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis.
J Infect Dis.
https://doi.org/10.1093/infdis/jiad317 - S Yamamoto, K Matsuda, K Maeda, Y Oshiro, N Inamura, T Mizoue, M Konishi, J S Takeuchi, K Horii, M Ozeki, H Sugiyama, H Mitsuya, W Sugiura and N Ohmagari.
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2.
BMC Infect Dis 23(1): 282.
https://doi.org/10.1186/s12879-023-08272-2 - J Terada-Hirashima, Y Takamatsu, Y Shimizu, Y Uemura, J S Takeuchi, N Tomita, K Matsuda, K Maeda, S Yamamoto, A Fukunaga, N Ohmagari, A Mikami, K Sonoda, M Ujiie, H Mitsuya and W Sugiura.
Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan.
Hum Vaccin Immunother 19(1): 2193074.
https://doi.org/10.1080/21645515.2023.2193074 - K Yamamoto, Y Ohsiro, T Suzuki, M Suzuki, S Miura, M Nagashima, N Iwamoto, J S Takeuchi, M Kimura, W Sugiura, S Nebuya, M Kurokawa and N Ohmagari.
Validation of the severe COVID-19 prognostic value of serum IL-6, IFN-lambda3, CCL17, and calprotectin considering the timing of clinical need for prediction.
PLoS One 18(3): e0279897.
https://doi.org/10.1371/journal.pone.0279897 - S Ishii, M Kimura, T Miyoshi-Akiyama, A Moriya, M Kurokawa, E Isaka, J Terada-Hirashima, J Takasaki, S Izumi, M Hojo and H Sugiyama.
Examination of the utility of the COVID-19 detection kit, TRC Ready® SARS-CoV-2 i for nasopharyngeal swabs.
Drug Discov Ther 17(2): 134-138.
https://doi.org/10.5582/ddt.2022.01106 - C Aoki-Utsubo, P Indrasetiawan, K Fukano, M Muramatsu, N Artanti, M Hanafi, H Hotta and M Kameoka.
Amentoflavone inhibits hepatitis B virus infection via the suppression of preS1 binding to host cells.
Microbiol Immunol 67(6): 281-292.
https://doi.org/10.1111/1348-0421.13064 - Y Li, S Yamamoto, Y Oshiro, N Inamura, T Nemoto, K Horii, J S Takeuchi, T Mizoue, M Konishi, M Ozeki, H Sugiyama, W Sugiura and N Ohmagari.
Comparison of risk factors for SARS-CoV-2 infection among healthcare workers during Omicron and Delta dominance periods in Japan.
J Hosp Infect 134: 97-107.
https://doi.org/10.1016/j.jhin.2023.01.018 - H Watanabe, T Iori, J W Lee, T S Kajii, A Takakura, R Takao-Kawabata, Y Kitagawa, Y Maruoka and T Iimura.
Association between an Increased Serum CCL5 Level and Pathophysiology of Degenerative Joint Disease in the Temporomandibular Joint in Females.
Int J Mol Sci 24(3).
https://doi.org/10.3390/ijms24032775 - S Yamamoto, K Matsuda, K Maeda, K Horii, K Okudera, Y Oshiro, N Inamura, J S Takeuchi, M Konishi, M Ozeki, T Mizoue, H Sugiyama, N Aoyanagi, H Mitsuya, W Sugiura and N Ohmagari.
Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave.
Int J Infect Dis 128: 347-354.
https://doi.org/10.1016/j.ijid.2023.01.023 - K Yato, M Matsuda, K Fukano, T Tanaka, K Moriishi, H Nishitsuji, K Shimotohno, K Tamura, T Wakita, M Muramatsu, T Kato and R Suzuki.
Identification of neutralizing epitopes in the preS2 domain of the hepatitis B virus.
Virus Res 323: 199014.
https://doi.org/10.1016/j.virusres.2022.199014 - N Nagata, T Takeuchi, H Masuoka, R Aoki, M Ishikane, N Iwamoto, M Sugiyama, W Suda, Y Nakanishi, J Terada-Hirashima, M Kimura, T Nishijima, H Inooka, T Miyoshi-Akiyama, Y Kojima, C Shimokawa, H Hisaeda, F Zhang, Y K Yeoh, S C Ng, N Uemura, T Itoi, M Mizokami, T Kawai, H Sugiyama, N Ohmagari and H Ohno.
Human Gut Microbiota and Its Metabolites Impact Immune Responses in COVID-19 and Its Complications.
Gastroenterology 164(2): 272-288.
https://doi.org/10.1053/j.gastro.2022.09.024 - 杉浦 亙, 竹内 (柴田) 潤子 and 菊地 正.
薬剤耐性HIVの現状と課題.
医学のあゆみ 284(9): 657-661.
https://cir.nii.ac.jp/crid/1520576900032883328